US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Birth Control

2,617.15

-14.7361-0.56%

Number of Gainers:4

Number of Losers:1

Number of Flat:1

PE:- -

High:2,631.50

Open:2,631.31

Low:2,601.20

Close:2,631.89

Volume:10.44M

Turnover:275.42M

Market Cap:41.46B

Float Cap:41.21B

Loading ...

XOMA Royalty Completes Generation Bio Acquisition and Merger

XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.

THOMSON REUTERS

Teva price target raised to $45 from $36 at Goldman Sachs

BRIEF-Mannkind Announces First Patient Enrolled In Inhale-1St Pediatric Study Evaluating Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes (T1d)

MannKind says first patient enrolled in INHALE-1ST study of Afrezza

FDA prüft Zulassung von Afrezza Inhalationsinsulin für Kinder und Jugendliche

MannKind Announces First Patient Enrolled in Inhale-1St Pediatric Study Evaluating Afrezza® for Youth With Newly-Diagnosed Type 1 Diabetes (T1d)

THOMSON REUTERS

NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM

Does Afrezza’s New Dosing Label Meaningfully Change The Bull Case For MannKind (MNKD)?

Simply Wall St.

NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM

Veru Inc. kündigt Veröffentlichung von Quartalsergebnissen und Geschäftsupdate an

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

Nodthera Appoints Geoff Mcdonough, M.d., as Chief Executive Officer

THOMSON REUTERS

Teva’s Sustainability Disclosures Face Rising Legal and Investor Risk Amid Global Compliance Demands

Veru Inc. Announces Date for Upcoming Annual Shareholders Meeting

Femasys enters distribution partnership with OR Consulting

Femasys Inc. Signs Swiss Distribution Agreement for FemBloc and FemaSeed

The Druckenmiller Connection: Meet the Man Behind Bessent and Warsh -- Barrons.com

Is Teva Pharmaceutical Industries (TEVA) Still Attractive After A 92% One-Year Share Price Surge

Simply Wall St.

The Bull Case For MannKind (MNKD) Could Change Following FDA-Backed Afrezza Dosing Label Update

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4584/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":2617.1519,"timestamp":1770670799999,"preClose":2631.888,"halted":0,"volume":10443445,"delay":0,"changeRate":-0.005599,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-14.736084,"latestTime":"02-09 16:00:00 EST","open":2631.306,"high":2631.5,"low":2601.1997,"amount":275421276.557991,"amplitude":0.011513,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770714000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.268897,"peRate":31.781727,"turnoverRate":0.006907,"increases":4,"decrements":1,"flats":0,"marketCap":41455475620,"floatMarketCap":41206112024},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":2631.5,"amplitude":0.011513,"preClose":2631.888,"low":2601.1997,"pbRate":"5.268897","latestPrice":2617.1519,"volume":10443445,"delay":0,"open":2631.306,"prevYearClose":2379.9924,"prevWeekClose":2631.888,"prevMonthClose":2591.3975,"prevQuarterClose":2379.9924,"fiveDayClose":2699.8396,"twentyDayClose":2443.2112,"sixtyDayClose":1932.974,"secType":"PLATE","market":"US","turnoverRate":0.006907,"peRate":31.781727,"marketCap":41455475620,"floatMarketCap":41206112024,"timestamp":1770670799999,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":4,"down":1,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610584661","title":"XOMA Royalty Completes Generation Bio Acquisition and Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2610584661","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610584661?lang=en_us&edition=fundamental","pubTime":"2026-02-10 05:56","pubTimestamp":1770674173,"startTime":"0","endTime":"0","summary":"Xoma ( ($XOMA) ) has provided an announcement. On February 6, 2026, XOMA Royalty completed a tender offer to acquire approximately 70% of Generatio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xoma-royalty-completes-generation-bio-acquisition-and-merger?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xoma-royalty-completes-generation-bio-acquisition-and-merger?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","GBIO","XOMA","BK4139"],"gpt_icon":0},{"id":"2610659736","title":"XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2610659736","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610659736?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:53","pubTimestamp":1770648780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUA6S1FPB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4584","XOMA","GBIO"],"gpt_icon":0},{"id":"2610658202","title":"Teva price target raised to $45 from $36 at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2610658202","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610658202?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:41","pubTimestamp":1770640861,"startTime":"0","endTime":"0","summary":"Goldman Sachs raised the firm’s price target on Teva (TEVA) to $45 from $36 and keeps a Buy rating on the shares. Shares have surged over the past ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-price-target-raised-to-45-from-36-at-goldman-sachs-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-price-target-raised-to-45-from-36-at-goldman-sachs-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0048573561.USD","IE0004086264.USD","LU1804176565.USD","LU2750360641.GBP","BK4585","LU0251142724.SGD","GSX","LU2471134952.CNY","LU2324357040.USD","LU2471134879.HKD","IE0002270589.USD","IE00B19Z3B42.SGD","LU2237443549.SGD","LU1983299246.USD","IE00B19Z3581.USD","BK4566","LU0345770308.USD","LU2237438978.USD","LU0742534661.SGD","LU2750360997.AUD","BK4007","BK4557","LU0345770993.USD","LU2471134523.USD","IE00BSNM7G36.USD","BK4516","LU2265009873.SGD","LU0106831901.USD","LU0251131958.USD","LU0096364046.USD","LU2237443978.SGD","LU1791807156.HKD","BK4533","LU1868837300.USD","LU2237443895.HKD","LU1868836914.USD","BK4504","BK4588","BK4550","LU2237443465.HKD","LU2237443622.USD","IE00BFXG1179.USD","LU1868836757.USD","LU1868836591.USD","BK4552","BK4127","LU1868837136.USD","BK4584","IE0004091025.USD","TEVA"],"gpt_icon":0},{"id":"2610310766","title":"BRIEF-Mannkind Announces First Patient Enrolled In Inhale-1St Pediatric Study Evaluating Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes (T1d)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610310766","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610310766?lang=en_us&edition=fundamental","pubTime":"2026-02-09 19:13","pubTimestamp":1770635582,"startTime":"0","endTime":"0","summary":"BRIEF-Mannkind Announces First Patient Enrolled In Inhale-1St Pediatric Study Evaluating Afrezza For Youth With Newly-Diagnosed Type 1 Diabetes (T1d)Feb 9 (Reuters) - MannKind Corp MNKD.O:MANNKIND ANN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUAB8KM3B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4584","MNKD"],"gpt_icon":0},{"id":"2610621634","title":"MannKind says first patient enrolled in INHALE-1ST study of Afrezza","url":"https://stock-news.laohu8.com/highlight/detail?id=2610621634","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610621634?lang=en_us&edition=fundamental","pubTime":"2026-02-09 19:11","pubTimestamp":1770635485,"startTime":"0","endTime":"0","summary":"MannKind (MNKD) announced that the first patient has been enrolled in INHALE-1ST, a clinical study evaluating the initiation of Afrezza Inhalation ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mannkind-says-first-patient-enrolled-in-inhale-1st-study-of-afrezza-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mannkind-says-first-patient-enrolled-in-inhale-1st-study-of-afrezza-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","BK4139","MNKD"],"gpt_icon":0},{"id":"2610063123","title":"FDA prüft Zulassung von Afrezza Inhalationsinsulin für Kinder und Jugendliche","url":"https://stock-news.laohu8.com/highlight/detail?id=2610063123","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610063123?lang=en_us&edition=fundamental","pubTime":"2026-02-09 19:05","pubTimestamp":1770635117,"startTime":"0","endTime":"0","summary":"Die US-Arzneimittelbehrde FDA hat im Oktober 2025 die berprüfung eines ergnzenden Biologics License Application  für Afrezza Inhalationspulver bei Kindern und Jugendlichen mit Typ-1- oder Typ-2-Diabetes angenommen. Die MannKind Corporation ist an diesem Verfahren beteiligt. Das voraussichtliche Datum für eine Entscheidung  ist der 29. Mai 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via GlobeNewswire  on February 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDLbvkJLW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014039.USD","LU2210150020.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","BK4585","BK4584","SG9999014005.SGD","LU0314104364.USD","IE00BKPKM429.USD","LU2095319765.USD","BK4139","BK4112","MNKD","IE00BGHQF748.EUR","NDAQ"],"gpt_icon":0},{"id":"2610457631","title":"MannKind Announces First Patient Enrolled in Inhale-1St Pediatric Study Evaluating Afrezza® for Youth With Newly-Diagnosed Type 1 Diabetes (T1d)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610457631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610457631?lang=en_us&edition=fundamental","pubTime":"2026-02-09 19:05","pubTimestamp":1770635100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUAB8KM3B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MNKD","BK4139","BK4584"],"gpt_icon":0},{"id":"2609357347","title":"NASDAQ TRADE HALT CONTINUES  TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2609357347","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609357347?lang=en_us&edition=fundamental","pubTime":"2026-02-08 16:28","pubTimestamp":1770539317,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUES  TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260208:nAQN2LLDUM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GBIO","BK4584"],"gpt_icon":0},{"id":"2609697547","title":"Does Afrezza’s New Dosing Label Meaningfully Change The Bull Case For MannKind (MNKD)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2609697547","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609697547?lang=en_us&edition=fundamental","pubTime":"2026-02-07 15:11","pubTimestamp":1770448296,"startTime":"0","endTime":"0","summary":"MannKind Corporation previously announced that the FDA approved an update to Afrezza’s Prescribing Information, revising starting mealtime doses for adults switching from injected or pump-delivered insulin based on recent modeling and clinical data.\nThis label change is noteworthy because it offers clearer conversion guidance for clinicians, potentially making transitions to Afrezza more clinically manageable while highlighting its pulmonary safety considerations.\nWith this labeling update...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/does-afrezzas-new-dosing-label-meaningfully-change-the-bull","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/does-afrezzas-new-dosing-label-meaningfully-change-the-bull","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4584","MNKD"],"gpt_icon":0},{"id":"2609510773","title":"NASDAQ TRADE HALT  TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2609510773","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609510773?lang=en_us&edition=fundamental","pubTime":"2026-02-07 08:50","pubTimestamp":1770425400,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260207:nAQN2LLALP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4584","GBIO"],"gpt_icon":0},{"id":"2608362924","title":"Veru Inc. kündigt Veröffentlichung von Quartalsergebnissen und Geschäftsupdate an","url":"https://stock-news.laohu8.com/highlight/detail?id=2608362924","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608362924?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:31","pubTimestamp":1770211908,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published the original content used to generate this news brief via GlobeNewswire  on February 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDLcB0qS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00BGHQF748.EUR","SG9999014005.SGD","IE00BKPKM429.USD","BK4183","VERU","BK4588","BK4112","SG9999014021.USD","IE00B64PRP62.GBP","BK4007","SG9999014039.USD","SG9999014013.SGD","LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","BK4557","BK4584","BK4585","NDAQ","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2608360492","title":"Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th","url":"https://stock-news.laohu8.com/highlight/detail?id=2608360492","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608360492?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:30","pubTimestamp":1770211800,"startTime":"0","endTime":"0","summary":"MIAMI, FL, Feb.  04, 2026  (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/04/3232036/11676/en/Veru-to-Report-Fiscal-2026-First-Quarter-Financial-Results-on-February-11th.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","VERU","BK4584","BK4183","BK4007"],"gpt_icon":0},{"id":"2608364881","title":"Nodthera Appoints Geoff Mcdonough, M.d., as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2608364881","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608364881?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:00","pubTimestamp":1770210005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nTUAC08YJ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4584","GBIO"],"gpt_icon":0},{"id":"2608323833","title":"Teva’s Sustainability Disclosures Face Rising Legal and Investor Risk Amid Global Compliance Demands","url":"https://stock-news.laohu8.com/highlight/detail?id=2608323833","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608323833?lang=en_us&edition=fundamental","pubTime":"2026-02-04 14:00","pubTimestamp":1770184820,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries Limited (TEVA) has disclosed a new risk, in the Environmental / Social category. Teva Pharmaceutical Industries Limi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tevas-sustainability-disclosures-face-rising-legal-and-investor-risk-amid-global-compliance-demands?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tevas-sustainability-disclosures-face-rising-legal-and-investor-risk-amid-global-compliance-demands?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","TEVA","LU1983299246.USD","LU2324357040.USD","BK4557","BK4559","BK4584","BK4007","BK4596","BK4566"],"gpt_icon":0},{"id":"2608338627","title":"Veru Inc. Announces Date for Upcoming Annual Shareholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2608338627","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608338627?lang=en_us&edition=fundamental","pubTime":"2026-02-04 06:42","pubTimestamp":1770158526,"startTime":"0","endTime":"0","summary":"Veru Inc. has announced that its Annual Meeting of Shareholders will be held on March 12, 2026, in Miami, Florida. During the meeting, shareholders will consider and act upon a proposal to amend the Company's 2018 Equity Incentive Plan, vote on a non-binding advisory proposal on executive compensation, and consider a proposal to approve the adjournment of the Annual Meeting if necessary or appropriate in the view of the Board of Directors, including to solicit additional proxies if there are not sufficient votes to approve any of the other proposals. Shareholders may also transact such other business as may properly come before the meeting and any adjournments thereof.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL657HNT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4584","BK4557","BK4007","VERU"],"gpt_icon":0},{"id":"2608872068","title":"Femasys enters distribution partnership with OR Consulting","url":"https://stock-news.laohu8.com/highlight/detail?id=2608872068","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608872068?lang=en_us&edition=fundamental","pubTime":"2026-02-03 22:20","pubTimestamp":1770128428,"startTime":"0","endTime":"0","summary":"Femasys (FEMY) announced a new strategic distribution partnership with OR Consulting to support the commercial launch of its product portfolio in S...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/femasys-enters-distribution-partnership-with-or-consulting-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/femasys-enters-distribution-partnership-with-or-consulting-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FEMY","BK4082","OR","BK4584","BK4539","BK4017"],"gpt_icon":0},{"id":"2608872101","title":"Femasys Inc. Signs Swiss Distribution Agreement for FemBloc and FemaSeed","url":"https://stock-news.laohu8.com/highlight/detail?id=2608872101","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608872101?lang=en_us&edition=fundamental","pubTime":"2026-02-03 22:15","pubTimestamp":1770128121,"startTime":"0","endTime":"0","summary":"Femasys Inc. announced a new strategic distribution partnership with OR Consulting to support the commercial launch of its product portfolio in Switzerland. The agreement covers FemBloc Permanent Birth Control, FemaSeed Intratubal Insemination, and additional fertility and women’s diagnostic health products. This partnership follows Femasys’ recent market entry in Spain and ongoing launch activities in France, expanding the company's commercial presence in Europe.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief via GlobeNewswire  on February 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL5vpdqC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","FEMY","SG9999014021.USD","LU2210149790.SGD","BK4585","SG9999014013.SGD","SG9999014005.SGD","BK4082","SG9999014039.USD","NDAQ","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","IE00B64PRP62.GBP","BK4539","LU0314104364.USD","LU2210150020.SGD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2608830848","title":"The Druckenmiller Connection: Meet the Man Behind Bessent and Warsh -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2608830848","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608830848?lang=en_us&edition=fundamental","pubTime":"2026-02-02 14:30","pubTimestamp":1770013800,"startTime":"0","endTime":"0","summary":"If President Donald Trump's pick for Federal Reserve chair, Kevin Warsh, is confirmed by the Senate, it will put Wall Street investor Stanley Druckenmiller in the unusual position of having mentored two of the most powerful financial leaders in Washington, nay the world, in Warsh and Treasury Secretary Scott Bessent, who also worked for Druckenmiller. It also means that Stan, or \"Druck\" -- he is known by both on the Street -- would be in the enviable position of having a direct connection to the heads of both the Fed and Treasury.Druckenmiller, 72, a highly influential, long-short macro investor with a sterling track record, has been critical of fiscal policy and particularly Fed policy in recent years. When asked about his acolytes, he sounds pleased they could be in a position to implement change.\"Stan has been a mentor to many, particularly in his approach to managing risk,\" says Paula Volent, chief investment officer of Rockefeller University. \"He also has a great track record in i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4561","LU1823568750.SGD","IE00BZ1G4Q59.USD","SG9999014880.SGD","LU2860962120.EUR","LU0642271901.SGD","LU0061474705.USD","LU0289960550.SGD","LU1988902786.USD","LU2108987350.USD","LU1496350171.SGD","LU1201861249.SGD","IE00BJJMRY28.SGD","LU0056508442.USD","LU2750360997.AUD","LU0965509010.AUD","LU1868837136.USD","LU0211328371.USD","IE00B7SZLL34.SGD","LU0342679015.USD","LU0882574139.USD","LU0719512351.SGD","LU1046421795.USD","LU0708995401.HKD","LU0234572021.USD","LU0061475181.USD","LU0302445910.USD","LU2242649171.HKD","IE00BK4W5M84.HKD","LU0149725797.USD","LU0348723411.USD","LU2089284900.SGD","BK4113","LU0210533765.USD","LU0251132253.USD","LU1261432733.SGD","LU1037948541.HKD","LU1778281490.HKD","LU0320765489.SGD","LU1839511570.USD","LU0106959298.USD","IE00B1XK9C88.USD","SGXZ51526630.SGD","BK4503","LU0210536198.USD","IE00BJTD4N35.SGD","IE00B4YYXB79.USD","LU1366333091.USD","LU0823421416.USD","LU0050427557.USD","LU2764263203.CNY","LU0072461881.USD","LU1066051498.USD","LU0069063385.USD","IE0003U64NQ7.SGD","LU1116320737.USD","BK4534","LU0965509101.SGD","LU2247934214.USD","LU0096362180.USD","LU1934455277.USD","BK4604","LU0980610538.SGD","LU1242518931.SGD","LU0353189763.USD","LU0265550946.USD","LU0964807845.USD","LU2592432038.USD","LU1280957306.USD","LU0640476718.USD","LU0957791311.USD","IE00BFSS7M15.SGD","LU0130102774.USD","LU1868836914.USD","LU0162691827.USD","LU1323610961.USD","BK4535","LU1815333072.USD","LU2237438978.USD","LU2505996509.AUD","BK4551","IE0004091025.USD","LU2764262908.HKD","LU0029864427.USD","LU1883839398.USD","IE00B19Z8X17.USD","LU0057025933.USD","LU1868837565.USD","LU2092627202.USD","LU2092937148.SGD","LU2077746001.SGD","MELI","LU0143863198.USD","LU0053687314.USD","AMZZ","LU1116320901.HKD","LU2065171402.SGD","LU1551013425.SGD","LU2362540622.SGD","LU1244550221.USD","LU1232071149.USD","LU0820561818.USD","LU2028103732.USD","LU1861558580.USD","SG9999018865.SGD","IE0004445239.USD","LU0648001328.SGD","LU0130103400.USD","LU0724617625.USD","LU2462157665.USD","SG9999014898.SGD","TEVA","AMZD","LU0823434583.USD","BK4579","SG9999015952.SGD","IE0005OL40V9.USD","LU1691799644.USD","LU1868837722.USD","LU2756315664.SGD","LU0672654240.SGD","LU2097829019.USD","IE00B3S45H60.SGD","LU1435385759.SGD","LU2403377893.USD","IE00BFSS8Q28.SGD","LU0310799852.SGD","LU1935043023.USD","LU0109394709.USD","LU0345769128.USD","IE00BK4W5L77.USD","LU0354030438.USD","LU0054578231.USD","LU2417539215.USD","NTRA","SG9999002232.USD","LU2087625088.SGD","LU0109392836.USD","LU2265009873.SGD","LU1066051225.USD","LU2362541513.USD","IE0001KFT4U8.USD","LU1069344957.HKD","IE00B775SV38.USD","LU0345768153.USD","LU0861579265.USD","LU2505996681.GBP","LU1242518857.USD","LU0143863784.USD","LU1429558221.USD","BK4592","LU2456880835.USD","LU2264538146.SGD","LU1037948897.HKD","LU0154236417.USD","LU0289941410.SGD","LU0689472784.USD","LU1064131342.USD","LU1035775433.USD","LU0323591593.USD","SGXZ31699556.SGD","LU0820562030.AUD","LU0096364046.USD","SG9999017495.SGD","LU2543165471.USD","LU2430703251.USD","IE00BJTD4V19.USD","LU2168563687.JPY","IE00BKDWB100.SGD","LU1074936037.SGD","SG9999000418.SGD","BK4559","LU0943347566.SGD","LU2089283258.USD","LU2746668974.SGD","LU0823411888.USD","LU1720051017.SGD","LU1084165304.USD","LU0289739343.SGD","LU1791710582.SGD","LU0210535034.USD","IE00BQXX3D17.EUR","LU1633808545.USD","LU0965509283.SGD","LU2125154778.USD","IE00BQXX3C00.GBP","LU0203202063.USD","LU1868836757.USD","IE00B1B80R65.USD","LU1718418525.SGD","GB00BDT5M118.USD","LU0256863902.USD","LU2430703095.HKD","IE00B8L5B284.USD","LU0079474960.USD","SG9999004303.SGD","LU0823434740.USD","LU1803068979.SGD","IE00B7KXQ091.USD","LU0456842615.SGD","IE00B5949003.HKD","LU1935043536.SGD","HK0000914660.USD","BK4550","LU0965508806.USD","LU0889565833.HKD","SG9999014906.USD","LU1145028129.USD","BK4220","LU2065171311.SGD","LU0053666078.USD","LU2324357040.USD","LU2756315318.SGD","LU2168564149.EUR","LU0053671581.USD","IE0034235303.USD","LU0648000940.SGD","TMF","IE00BJJMRX11.SGD","SG9999018857.SGD","LU2250418816.HKD","LU0431992006.USD","LU0276348264.USD","BK4543","LU0312595415.SGD","LU2211817866.USD","LU1861215975.USD","LU0868486357.SGD","LU2023250330.USD","LU0208291251.USD","LU1267930730.SGD","IE000KEQY171.SGD","LU1868837300.USD","LU2065170008.USD","LU0823421333.USD","LU0820561909.HKD","LU0198837287.USD","LU2452424414.USD","LU2471134952.CNY","IE00BQXX3F31.USD","LU2317271919.USD","LU0979878070.USD","LU2471134879.HKD","LU2211815571.USD","LU2125154935.USD","LU0158827948.USD","LU2168564495.EUR","BK4612","LU2463028550.USD","LU2362541273.HKD","LU0985320562.USD","LU2083900584.USD","LU0472753341.HKD","BK4557","SGXZ99366536.SGD","LU0345774391.USD","LU0265550359.USD","LU0788109477.HKD","LU1989764748.USD","IE00BYQQ9H92.USD","LU0158827781.USD","LU0082616367.USD","LU0708994859.HKD","LU1868838027.USD","LU0070217475.USD","LU2023250504.SGD","IE00BMPRXQ63.HKD","IE000W1ABFV2.USD","LU1267930490.SGD","LU1316542783.SGD","LU1674673428.USD","LU2602419157.SGD","IE00B775H168.HKD","LU1244550494.USD","IE00BN29S564.USD","LU1119994496.HKD","LU0210528500.USD","LU0238689110.USD","LU2357305700.SGD","LU1066053197.SGD","LU0127658192.USD","IE0009356076.USD","BK4527","LU2065169927.USD","SG9999002224.SGD","LU1791710400.SGD","BK4007","LU0310800379.SGD","IE0004086264.USD","LU0203201768.USD","LU0320765059.SGD","LU2361044865.SGD","LU0289961442.SGD","LU0787776722.HKD","LU1804176565.USD","LU1496350502.SGD","IE00B8HQ1Z84.USD","LU2242650005.HKD","LU0466842654.USD","LU1914381329.SGD","LU2746668461.USD","LU0072462426.USD","LU2552382132.HKD","IE00B3SWFQ91.USD","BK4524","LU2063271972.USD","LU1989764664.SGD","BK4554","LU1153585028.USD","LU1861559042.SGD","LU2420271590.USD","INSM","LU2355687059.USD","LU2168564222.USD","LU2326559502.SGD","LU1852331112.SGD","IE00B1BXHZ80.USD","LU0528227936.USD","LU0345768740.USD","LU0211327993.USD","LU0308772762.SGD","IE00B19Z3B42.SGD","BK4548","AMZY","LU2360107168.USD","LU0175139822.USD","LU0107464264.USD","BK4566","IE00BKPKM429.USD","LU1814569148.SGD","IE00BFXG0V08.USD","LU1934455194.USD","SGXZ23171101.USD","LU0417517546.SGD","LU2271345857.HKD","LU1934455863.HKD","LU0215105999.USD","LU2361045086.USD","LU1861220033.SGD","LU1935042991.SGD","LU0889565916.HKD","LU0456855351.SGD","LU0256863811.USD","LU0011850046.USD","LU2381873111.SGD","LU0267386448.USD","LU2106854487.HKD","LU0061474960.USD","LU2487616109.SGD","LU2213496289.HKD","LU1201861165.SGD","IE00B4JS1V06.HKD","LU0128525929.USD","LU1935042488.USD","LU1868836591.USD","LU1935042215.USD","LU0077335932.USD","LU0532187761.SGD","LU2720916845.USD","AMZW","LU0157215616.USD","LU2360106780.USD","LU2552382215.SGD","TLTW","LU2471134796.USD","LU1917777945.USD","LU1366192091.USD","BK4581","USAW.SI","LU1880398471.USD","LU0316494557.USD","LU0109391861.USD","LU2290526834.HKD","IE00B19Z8W00.USD","BK4122","LU2237957902.USD","IE00B0JY6N72.USD","IE00B5TLWC47.USD","LU0070302665.USD","LU1720051108.HKD","LU2023251221.USD","SG9999015978.USD","LU0354030511.USD","LU2168564065.EUR","LU2087621335.USD","SG9999001077.SGD","LU0080751232.USD","LU2360032135.SGD","SGXZ81514606.USD","BK4588","LU0353189680.USD","IE00BWXC8680.SGD","LU2896262040.SGD","LU1551013342.USD","IE000YTNTUN2.SGD","IE000ITXATA3.USD","LU1235294995.USD","LU1127390331.HKD","LU0234570918.USD","LU2750360641.GBP","LU0683600562.USD","IE00BMPRXR70.SGD","LU1674673691.USD","LU2430703178.SGD","SG9999015945.SGD","CPNG","LU0345774631.USD","BK4532","IE00B19Z3581.USD","LU1066051811.HKD","LU1983299246.USD","LU2461242641.AUD","HK0000914686.HKD","LU0170899867.USD","LU1629891620.HKD","LU0048584097.USD","IE0002270589.USD","LU1244550577.SGD","SG9999014914.USD","LU2237957811.SGD","LU2361044949.HKD","LU0345770308.USD","LU0511384066.AUD","IE00BKVL7J92.USD","LU0320765992.SGD","LU1974910355.USD","IE00B19Z9505.USD","AZYY","SG9999015986.USD","LU2471134523.USD","LU0314104364.USD","IE00B0169N27.USD","BK4507","LU0390134368.USD","LU1861127337.USD","LU2552382058.USD","IE00BGV7N243.SGD","LU2275660780.HKD","LU1880398554.USD","BK4584","LU1267930573.SGD","LU2054465674.USD","LU0097036916.USD","BK4139","BK4598","LU2236285917.USD","LU0345769631.USD","LU0786609619.USD","BK4538","LU0345770993.USD","IE0004445015.USD","LU2764263039.SGD","BK4585","AMZU","LU2279701549.SGD","LU1548497426.USD","BK4596","IE0009G5SDU7.USD","IE00BMPRXN33.USD","LU2111349929.HKD","BK4533","LU0494093205.USD","IE00BJLML261.HKD"],"gpt_icon":1},{"id":"2607079134","title":"Is Teva Pharmaceutical Industries (TEVA) Still Attractive After A 92% One-Year Share Price Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2607079134","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607079134?lang=en_us&edition=fundamental","pubTime":"2026-01-31 12:35","pubTimestamp":1769834130,"startTime":"0","endTime":"0","summary":"If you are wondering whether Teva Pharmaceutical Industries is priced for further gains or already reflecting most of the good news, starting with a clear look at its current valuation can help you frame that question.\nTeva’s share price closed at US$34.08, with returns of 7.1% over 7 days, 9.2% over 30 days, 10.1% year to date, 92.2% over 1 year, 216.7% over 3 years and 178.4% over 5 years. This naturally raises questions about what is already built into the price and what might still be on...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/is-teva-pharmaceutical-industries-teva-still-attractive-afte-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/is-teva-pharmaceutical-industries-teva-still-attractive-afte-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","TEVA","BK4596","LU1983299246.USD","BK4559","BK4588","LU2324357040.USD","BK4584","BK4566","BK4585","BK4557","DCF"],"gpt_icon":0},{"id":"2607078110","title":"The Bull Case For MannKind (MNKD) Could Change Following FDA-Backed Afrezza Dosing Label Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2607078110","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607078110?lang=en_us&edition=fundamental","pubTime":"2026-01-31 04:37","pubTimestamp":1769805430,"startTime":"0","endTime":"0","summary":"MannKind Corporation recently received FDA approval for an update to Afrezza’s Prescribing Information, refining recommended starting mealtime doses when adults switch from injected or pump-based insulin to the inhaled therapy, based on new modeling and clinical data.\nThis label change is significant because clearer conversion guidance may influence how comfortably physicians transition suitable diabetes patients to Afrezza’s ultra rapid-acting inhaled insulin option, while keeping its known...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/the-bull-case-for-mannkind-mnkd-could-change-following-fda-b","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/the-bull-case-for-mannkind-mnkd-could-change-following-fda-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","MNKD","BK4584"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":39,"code":"91000000","status":"200"}]}}